Finance entity
All 1 tracked stories fall under one category: earnings. Fosun Kite is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Fosun Kite is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline. We currently track 1 Finance story that mention Serplulimab, all published on March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 119 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Serplulimab. Shared-story counts are live from our verified record — not editorial picks.
Annual Results
Official release of 2025 financial performance data to global markets.
Global Partnership
Strategic agreement signed for the distribution of biosimilars in emerging markets.
CAR-T Milestone
Fosun Kite announces expanded indications for Yi Kai Da CAR-T therapy.
Regional Launch
Serplulimab receives regulatory approval in additional Southeast Asian markets.
Fosun Pharma reported robust 2025 financial results, driven by a record contribution from innovative drugs and successful expansion into Southeast Asian markets. The company's strategic focus on high-barrier biologics and R&D has solidified its transition from a generic-focused manufacturer to a global innovation leader.
Serplulimab is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
